Showing results (311-320 of 494) with videos related to
Sort By:
Pageof 50
Biomed Research International|February 25, 2021
Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAsEwa Paszkiewicz-Kozik, Agnieszka Paziewska, Maria Kulecka, et al.The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trialAlexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|July 17, 2007
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumorsJerzy Lasota, Anna Jerzak vel Dobosz, Bartosz Wasag, et al.Eclinicalmedicine|September 21, 2023
An interpretable AI model for recurrence prediction after surgery in gastrointestinal stromal tumour: an observational cohort studyDimitris Bertsimas, Georgios Antonios Margonis, Seehanah Tang, et al.Cells|February 13, 2021
Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort AnalysisMateusz Jacek Spałek, Jan Poleszczuk, Anna Małgorzata Czarnecka, et al.Melanoma Research|May 22, 2018
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitorsPaweł Teterycz, Paulina Jagodzińska-Mucha, Bożena Cybulska-Stopa, et al.The Lancet. Oncology|December 14, 2011
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsHeikki Joensuu, Aki Vehtari, Jaakko Riihimäki, et al.Nature Genetics|July 11, 2018
Genetic determinants of co-accessible chromatin regions in activated T cells across humansRachel E Gate, Christine S Cheng, Aviva P Aiden, et al.Nature|August 12, 2021
Cycling cancer persister cells arise from lineages with distinct programsYaara Oren, Michael Tsabar, Michael S Cuoco, et al.Pageof 50